Loading…
← CockpitCompetitor Analysis › 4544.T H.U.Group Holdings, Inc.Open in the cockpit ↗

H.U.Group Holdings, Inc.4544.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical/Nursing Services

Japan's largest clinical laboratory testing operator, running diagnostic tests for hospitals and clinics nationwide.

≈ Japan's Quest Diagnostics / LabCorpMomentum leader 90
Mkt cap
$1.44B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$5.27M
20-day average traded
Fwd P/E
39.9×
forward earnings
ROIC−WACC
-1.7 pp
WACC 5.0%
Hurdle
+8 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · JPY¥4,017
1D-0.1%
1W+3.5%
1M+8.9%
3M+10.6%
6M+24.4%
YTD+18.8%
1Y+3.0%
ATR %2.5%
52w lowhigh1.4% off high

What H.U.Group does

Japan's largest clinical laboratory testing operator, running diagnostic tests for hospitals and clinics nationwide.

Earns testing fees per sample from hospitals and clinics that send blood and tissue to its laboratories, plus sales of diagnostic reagents through Fujirebio, which it owns, including tests used in Alzheimer's diagnosis. Japan's national fee schedule sets test prices, so volume and efficiency matter more than pricing.

In one line: Japan's Quest Diagnostics / LabCorp.

Products and services

  • Clinical laboratory testing
  • Genetic/specialty testing
  • Healthcare data services

Customers

  • Hospitals
  • Clinics
  • Pharmaceutical companies (clinical trial testing)

Where it sits in the supply chain

  • Health care
  • Clinical laboratory testing
  • Diagnostic testing services for…

What could go right

  • Aging population/test volume growth

What could go wrong

  • Reimbursement price cuts by government

Moat: narrow (scale, installed base, regulatory licence). Largest lab-testing network in Japan gives scale economics that smaller labs cannot match.

Headquarters: Tokyo, Japan · Founded: 1970 · Employees: 5,157

Named competitors

H.U.Group at a glance

Size H.U.Group (4544.T) is a Japan Health Care company (Medical/Nursing Services) with a market value of $1.44B, the 587th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,017 on 18 Nov 2026.

Performance Over six months the shares gained 24.4%, against +14.0% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 0.5% over the last twelve months (peer median +7.9%); the operating margin is 2.8% (peer median 6.2%).

Valuation It trades at 39.9× forward earnings against a peer median of 23.7× (4th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.7 points below its cost of capital (5.0% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 20264544.T 127Peer median 111
Six months, rebased to 100: H.U.Group against the median of its 20 peers (local-currency closes).

H.U.Group financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥249B¥247B¥243B¥237B¥261B
Revenue growth—+2%+3%-9%—
Gross profit¥72.4B¥70.8B¥61.3B¥57.3B¥84.5B
EBITDA¥27.7B¥26.5B¥23.1B¥16.8B¥43.1B
Net income¥9.96B¥6.82B¥2.76B-¥7.55B¥15.7B
Free cash flow¥21.1B¥19.2B¥20.9B¥4.18B¥18.3B
Capital expenditure¥5.10B¥4.86B¥10.3B¥17.6B¥21.7B
Total debt¥60.3B¥74.3B¥86.7B¥81.9B¥77.2B

Quarterly statements and history in the cockpit →

H.U.Group competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%USPHTDOC1833AGLLMRIWGSCLARIAMBEASNDADIAPSNLPNTGOPKMETROPOLISVIJAYA300244NUTXEMEISGDRX4544.T6-month return →1-month return →
Up and to the right = strong over both horizons. H.U.Group is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×USPH1833AGLLMRIWGSCLARIAMBEADIAPNTGMETROPOLISVIJAYA300244NUTXGDRX6038824544.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. H.U.Group is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%USPHTDOC1833CLARIMETROPOLISNUTX4544.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. H.U.Group is the large dot.

H.U.Group competitors and peer comparison

Head to head with its named competitors (4544.T vs DGX vs LH vs 4694.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
H.U.Group 4544.T$1.44B+24%+1%3%39.9×9.7%
Quest Diagnostics DGX$28.6B+34%+9%15%22.4×7.2%
Labcorp LH$30.1B+44%+6%11%19.3×14.5%
BML 4694.T$932M+12%+4%7%19.8×-9.0%

How H.U.Group compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

H.U.Group against its 20 peers (data as of 18 Nov 2026)
Measure4544.TPeer medianRank in peer set
1-month return+8.9%-1.6%5th highest of 21
6-month return+24.4%+14.0%8th highest of 21
Distance from 52-week high-1.4%-23.8%highest of 21
Revenue growth (TTM)+0.5%+7.9%7th lowest of 21
Operating margin2.8%6.2%8th lowest of 21
Forward P/E39.9×23.7×4th most expensive of 16
Growth the price implies (Req g, 7 yrs)9.7%6.5%6th most demanding of 15
Growth delivered (Del g)+2.1%+9.5%4th lowest of 15
Hurdle (Req g minus delivered)+7.6 pp+1.3 pp6th most demanding of 15
ROIC minus cost of capital-1.7 pp-3.6 pp8th highest of 20
EV / EBITDA8.9×11.7×5th cheapest of 14
Net debt / EBITDA0.6×2.8×5th least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%

Questions

Who are H.U.Group's main competitors?
Named competitors: Quest Diagnostics (DGX), LabCorp (LH), BML Inc (4694.T). The cockpit's measured peer set (industry) also includes U.S. Physical Therapy (USPH), Teladoc Health (TDOC), Ping An Healthcare and Technology (1833.HK), agilon health (AGL), Lumexa Imaging (LMRI), GeneDx (WGS).
Is H.U.Group expensive compared with its peers?
On forward p/e it trades at 39.9× against a peer median of 23.7×, 4th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has H.U.Group stock performed?
Over six months to 18 Nov 2026 the shares returned +24.4% against +14.0% for the median peer; over one year +3.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.